Table 3.
Results of subgroup analyses
| Subgroups and time period | Number of events |
Incidence rate ratio (95% CI) |
Number of events |
Incidence rate ratio (95% CI) |
|---|---|---|---|---|
| BNT162b2 vaccine | ||||
| Sex | Men | Women | ||
| Baseline | 450 | 130 | ||
| First dose | ||||
| 0–13 days after | 13 | 0.45 (0.19–1.08) | 5 | 0.65 (0.17–2.48) |
| 14–27 days after | 6 | 0.26 (0.08–0.81) | 6 | 0.93 (0.28–3.12) |
| Second dose | ||||
| 0–13 days after | 19 | 0.77 (0.40–1.50) | 6 | 1.18 (0.41–3.38) |
| 14–27 days after | 18 | 1.00 (0.56–1.79) | 9 | 1.52 (0.62–3.74) |
| Age groups | 65 years old or older | Under 65 years old | ||
| Baseline | 353 | 227 | ||
| First dose | ||||
| 0–13 days after | 11 | 0.40 (0.16–1.02) | 7 | 0.77 (0.33–1.80) |
| 14–27 days after | 11 | 0.54 (0.21–1.35) | 1 | 0.14 (0.02–1.20) |
| Second dose | ||||
| 0–13 days after | 14 | 0.71 (0.34–1.50) | 11 | 1.12 (0.53–2.39) |
| 14–27 days after | 21 | 1.22 (0.67–2.22) | 6 | 0.88 (0.38–2.03) |
| History of different cardiovascular conditions | Coronary heart disease | Cerebrovascular disease | ||
| Baseline | 342 | 242 | ||
| First dose | ||||
| 0–13 days after | 8 | 0.74 (0.35–1.58) | 9 | 0.97 (0.48–1.93) |
| 14–27 days after | 5 | 0.71 (0.28–1.83) | 4 | 0.69 (0.25–1.91) |
| Second dose | ||||
| 0–13 days after | 9 | 0.98 (0.48–1.99) | 12 | 1.42 (0.76–2.67) |
| 14–27 days after | 13 | 1.38 (0.76–2.49) | 11 | 1.32 (0.67–2.57) |
| CoronaVac vaccine | ||||
| Sex | Men | Women | ||
| Baseline | 704 | 283 | ||
| First dose | ||||
| 0–13 days after | 19 | 0.37 (0.18–0.76) | 8 | 0.57 (0.22–1.48) |
| 14–27 days after | 17 | 0.42 (0.21–0.82) | 11 | 0.89 (0.41–1.92) |
| Second dose | ||||
| 0–13 days after | 20 | 0.60 (0.33–1.11) | 10 | 1.08 (0.50–2.33) |
| 14–27 days after | 18 | 0.63 (0.37–1.08) | 12 | 1.53 (0.70–3.38) |
| Age groups | 65 years old or older | Under 65 years old | ||
| Baseline | 697 | 290 | ||
| First dose | ||||
| 0–13 days after | 23 | 0.50 (0.26–0.97) | 4 | 0.15 (0.03–0.67) |
| 14–27 days after | 23 | 0.61 (0.32–1.18) | 5 | 0.24 (0.08–0.72) |
| Second dose | ||||
| 0–13 days after | 18 | 0.54 (0.28–1.02) | 12 | 1.08 (0.59–1.98) |
| 14–27 days after | 22 | 0.86 (0.50–1.46) | 8 | 0.74 (0.34–1.60) |
| History of different cardiovascular conditions | Coronary heart disease | Cerebrovascular disease | ||
| Baseline | 522 | 472 | ||
| First dose | ||||
| 0–13 days after | 8 | 0.49 (0.23–1.04) | 13 | 0.80 (0.45–1.42) |
| 14–27 days after | 12 | 0.73 (0.39–1.34) | 11 | 0.72 (0.39–1.33) |
| Second dose | ||||
| 0–13 days after | 7 | 0.54 (0.25–1.15) | 19 | 1.36 (0.83–2.22) |
| 14–27 days after | 13 | 1.05 (0.59–1.87) | 14 | 1.11 (0.63–1.96) |